Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
Stopped early · Phase 1
Conditions studied: Advanced Malignant Solid Tumors, Metastatic Malignant Solid Tumors
In brief
The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer. Trial details include: * The trial duration for an individual participant will be up to approximately 11 months. * The treatment duration for an individual participant will be up to approximately 4 months (the duration of treatment may vary for each participant) and the follow-up duration for an individual participant will be approximately 6 months. Participation in the trial will require visits to the site. All participants will receive active drug; no one will be given placebo.
Key facts
- Study ID
- NCT06573294
- Run by
- Genmab
- People needed
- 23
- Starts
- 2024-08-28
- Expected to finish
- 2026-04-07
- Last updated by the study team
- 2026-05-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- SCRI Oncology Partners — Nashville, Tennessee, United States
- South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas, United States
- National Cancer Center, Tsukiji 5-1-1 — Tokyo, Japan
- Hospital Universitari Vall d'Hebron — Barcelona, Spain
- Start Madrid Centro Integral Oncologico Clara Campal CIOCC — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.